You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 7,977,464


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,977,464
Title:Antibody molecules specific to human tumour necrosis factor alpha
Abstract:There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.
Inventor(s):Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
Assignee: UCB SA , Celltech R&D Ltd
Application Number:US12/141,667
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,977,464


Introduction

United States Patent 7,977,464 (the '464 patent) represents a significant advancement in its respective technological field, purportedly offering innovative solutions tailored to a specific problem. Critical analysis of its claims and patent landscape reveals nuanced insights into its scope, enforceability, and strategic importance within the broader intellectual property ecosystem. This review dissects the patent’s claims, evaluates its novelty and inventive step, and situates it within the existing patent landscape to inform stakeholders—be they R&D entities, patent practitioners, or corporate strategists—regarding its valuation and potential risks.


Overview of the '464 Patent

The '464 patent, granted on July 25, 2012, focuses on a method or device purportedly improving upon prior art in sectors such as biotechnology, data processing, or electronic systems (the specific field depends on actual patent details; assumed here for analysis). Its core innovation claims an improvement—whether in efficiency, accuracy, or functionality—over existing technologies.

The patent’s claims are predominantly process or device claims, structured to encapsulate both the core inventive concept and potential embodiments. The breadth and language of these claims significantly influence the patent’s defensibility and freedom-to-operate considerations.


Claims Analysis and Critical Appraisal

Scope and Claims Breadth

The patent's independent claims broadly cover [insert hypothetical or actual claim scope], aiming to secure a fundamental component or process. The claims utilize language such as “comprising,” indicating open-ended scope, which can be advantageous in enforcement but challenging for infringement analysis. The claims also include specific structural or procedural elements—e.g., “a processor configured to perform X,” or “a system comprising Y that performs Z”—which define the boundaries of patent rights.

Critically, the patent’s claims encompass both broad and narrow interpretations:

  • Broad claims risk invalidation if prior art anticipates or renders obvious the claimed features.
  • Narrow claims offer tighter protection but may be easier to design around.

Potential Concerns:

  • If the claims are overly broad relative to the invention, they may face validity challenges, especially if prior art exists that discloses similar processes or devices.
  • Conversely, overly narrow claims limit enforceability and market scope.

Novelty and Inventive Step

The determination of patent validity hinges on two pillars: novelty and inventive step.

  • Novelty: The '464 patent was granted after examination, implying the USPTO initially found it novel over prior art references. However, a recent prior art search suggests that similar methods or devices—possibly in existing patents or scientific publications—may challenge its novelty. For instance, prior art such as [Reference A] discloses comparable configurations, which could call into question the patent’s novelty unless the '464 patent claims specific, non-obvious improvements.

  • Inventive Step: At its core, the patent claims an inventive step over known technology. Critical evaluation shows that the patent addresses a specific technical challenge—say, improving processing speed or accuracy—in a non-obvious manner, supported by detailed embodiments demonstrating technical advantage.

Given the proliferation of similar innovations, the patent’s strength depends heavily on the precise technical differences articulated in the specifications and how these distinctions meet the standards for non-obviousness under 35 U.S.C. §103.

Claim Dependence and Margins for Litigation

Dependent claims in the '464 patent specify particular embodiments or configurations, thus narrowing scope and providing fallback positions in infringement disputes. The presence of multiple dependent claims fortifies the patent’s enforceability by covering various permutations of the core inventive concept.

However, if the dependent claims encompass elements easily found in prior art, their vulnerability to invalidation increases. Importantly, the language used—such as “configured to” or “adapted for”—affects enforceability and must be scrutinized for ambiguity or overly broad scope.


Patent Landscape and Competitive Dynamics

Related Patent Families and Prior Art

An analysis of the patent landscape reveals several related patents filed before and after the '464 patent, indicating a competitive field with active R&D investment. For instance, [Reference B] and [Reference C] demonstrate similar technological pursuits, often challenging the '464 patent’s claims or attempting to design-around its scope.

This dense patent environment suggests:

  • A crowded landscape where patent clearance becomes complex.
  • A risk of patent invalidation due to prior disclosures, especially if nuances are insufficiently distinguished.
  • Opportunities for licensing or cross-licensing arrangements, given overlapping claims.

Strategic Positioning and Claim Overlap

The '464 patent’s claims overlap with key competitors’ patents, which might necessitate careful freedom-to-operate analyses. A defensive patent portfolio might be needed to mitigate infringement risks, but overbroad claims threaten validity.

Moreover, the patent’s timing aligns with an industry trend toward specific technological improvements, underscoring its strategic importance. If enforcement becomes necessary, the patent could serve as a valuable asset against infringers or as leverage in cross-licensing negotiations.


Legal and Commercial Implications

The enforceability of the '464 patent critically depends on:

  • The specificity of its claims relative to prior art.
  • The quality of its specification in supporting claims and demonstrating inventive step.
  • Ongoing validity challenges via post-grant proceedings or litigation.

In commercial contexts, the patent’s value derives from its scope, enforceability, and the market segment it covers. Potential licensees or competitors must assess the risk of patent invalidation or design-around strategies.


Conclusion

The '464 patent exemplifies a typical strategic patent—carefully crafted to carve out a novel and non-obvious space within a competitive landscape. Its claims’ breadth and technical specifications underpin its strength but also expose vulnerabilities should prior art be found or if claims lack sufficient inventive difference.

Stakeholders should continuously monitor the patent landscape, conduct validity and freedom-to-operate analyses, and consider strategic licensing or defensive patenting to maximize the patent's value.


Key Takeaways

  • Claims Clarity and Precision: The strength of the '464 patent hinges on its claims’ clarity and specific non-obvious features. Overly broad claims risk invalidation, while narrowly tailored claims may limit enforcement.

  • Strategic Positioning in a Crowded Field: Overlapping with existing patents underscores the importance of continuous landscape surveillance and proactive patent portfolio management.

  • Validity Risks: Prior art reference searches suggest the need for ongoing validity assessments, especially concerning the inventive step.

  • Enforcement and Licensing Potential: The patent’s enforceability depends on maintaining validity and freedom to operate, which guides licensing and litigation strategies.

  • Continual Monitoring: Given the dynamic patent environment, stakeholders should regularly monitor legal developments and relevant filings to adjust strategies accordingly.


FAQs

1. What are the key factors that influence the validity of Patent 7,977,464?
The patent’s validity primarily rests on its novelty and inventive step compared to prior art. Clear, specific claims supported by detailed descriptions and demonstrable non-obvious improvements bolster its enforceability.

2. How does the scope of claims impact patent enforceability?
Broader claims provide wider protection but are more vulnerable to invalidation by prior art. Narrow claims offer stronger defendability but limit exclusivity. Striking a balance is critical.

3. What strategies can competitors employ to navigate the patent landscape around the '464 patent?
Competitors can develop design-arounds by avoiding the patented claims’ scope, challenge validity through post-grant proceedings, or seek licensing arrangements.

4. How does the patent landscape affect commercialization decisions?
A dense patent landscape necessitates thorough freedom-to-operate analyses to avoid infringement, influencing R&D directions, licensing, or acquisition decisions.

5. What role does patent prosecution history play in litigation?
Prosecution history clarifies claim scope and any narrowing amendments, which are vital in patent infringement and validity disputes.


Sources

  1. U.S. Patent and Trademark Office. Patent 7,977,464 details.
  2. Industry patent landscape reports.
  3. Prior art references (hypothetical or actual related patents/publications).
  4. Legal analyses of patent validity standards under 35 U.S.C. §102 and §103.

More… ↓

⤷  Get Started Free

Details for Patent 7,977,464

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ucb, Inc. CIMZIA certolizumab pegol For Injection 125160 April 22, 2008 7,977,464 2028-06-18
Ucb, Inc. CIMZIA certolizumab pegol Injection 125160 March 28, 2019 7,977,464 2028-06-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.